ORLANDO -- Barely half of patients with atrial fibrillation who were prescribed rivaroxaban (Xarelto) to prevent stroke remained on the treatment after 2 years, but their adherence was still better than Afib patients on warfarin or dabigatran (Pradaxa), researchers said here.
Congestive heart failure (with decreased ejection fraction) has always been recognized as a risk factor for stroke or systemic embolism in patients with atrial fibrillation (AF) and is included in the CHA2DS-VASc risk score calculation.
Atrial fibrillation (AF) may increase the risk of dementia, according to a new study conducted in the Netherlands. The study looked at 20 years of follow-up data on over 6000 people, and found that younger participants with a longer duration of AF had the highest risk of dementia.
Catheter ablation offers an appealing option for patients with atrial fibrillation (AF) in whom rhythm control is desired. However, the success rate of the procedure remains somewhat dismal, with only 30% to 40% of persons achieving long term rhythm control. There are many theories as to why AF ablation may have limited success, including multiple sites of AF origination.
Atrial fibrillation (AF) has the luxury (and curse) of being one of those conditions for which large scale randomized clinical trials (such as RELY, ROCKET-AF, ARISTOTLE, ENGAGE-TIMI48) have paved the way for understanding risk and guiding disease management.
In dementia-free older adults at high risk for cardiovascular disease, impaired executive function appears to be associated with higher risk of incipient coronary heart disease and stroke, a meta-analysis of prospective observational studies now shows.
At the American College of Physicians Internal Medicine Meeting 2015 in Boston, Peter Zimetbaum, MD, Associate Professor of Medicine, Harvard Medical School, presented an “Update In Cardiology.” Here are the highlights of his presentation and the implications for clinical practice.